Dr. Helen Collins
you, Thank Aron.
We that In macrophages cancer two in the nine the excited eradicate programs. we’re progress targeting in made developing immune antibody receptor on different on in cabiralizumab, across the tumor micro to oncology, cells are slide I’ll with development environment. start the our to about cells CSF-X oncology PVNS. our rationale by
trial. the combining XXXX, We end enrollment cabira’s at the PD-X cohorts remove BMS’s to achieved innovation on T-cells. with in goal are Opdivo macrophages our Xb CDA Phase of complete associated this inhibitor We positive CSF-XR of to of tumor checkpoint reduce the to
with on line can in patients see and patients last data more Based XX, to data you will XXX encouraging reported across give BMS and we safety slide we decided additional shown us cancer. patients pancreatic on different and approximately As of we the seven settings. this tumor than late pancreatic enrolled worth enroll XX efficacy cancer, pancreatic fall,
was from to cohort pancreatic patients slide Aron patients results The responses or tumors with reported us responses our safety observing stable on data treatment pancreatic first are well summarized particular, that this study from were objective, mentioned, along point shown XX. durable with not pancreatic as non-chemotherapy XX% has from unprecedented cancer alone XXX are initial to PD-X with November, pancreatic on the patients initial physicians BMS, in cancer we cancer. is which data efficacy as cancer. trial. last As microsatellite in inhibition whose MSS In the of The
pancreatic so study enthusiastic benefit, be five context. serves setting, had MSS, the patients the explainable KOLs In the of patients of about at are a durable Opdivo years. the this why our clinical one Pancreatic cabira preliminary cancer cancer to had understand XX% of are To are only setting in responses which results need. need all metastatic unmet alone. Opdivo year data, by of put into at disease As X% is in and who tremendous XX% and not the alive
patients an months. we later survival in overall is at therapeutic reported X-FU durability and and last with and cabira six data As plus saw we the most of nine rate response confirmed X.X% leucovorin with approved of in response the of chemo an cancer this the a fall, almost Opdivo the recently pancreatic second XX% Aron In months cut-off. rate mentioned, that objective in from Onivyde of objective to disease five combination Onivyde time and extending presented data, with comparison, line
safety, adverse is cabira related treatment data, In moving Opdivo asymptomatic ALT. terms monotherapy profile with creating BMS and common in of with monotherapy, these the cabira. and consistent serum on such was as elevations event events liver enzymes AST were adverse kinase ahead the Based most
in cabira with have their in Also XX trial future of with combination without are alone locally setting enrolling Phase X patients development. X this in in depicted pancreatic Opdivo advanced collaboration with they taken with data that example, Five ideal the For clinical and approximately believe or synergy or Ono, metastatic control for cancer. advanced this cancer determine way and Phase X therapy also others well they either line in demonstrated tests combined PD-X quickly slide from and their second BMS XXX a the trial first will manufacturing. The pancreatic include combination. trial is the presented based and Prime we are of support of CSF-XR cabira preclinical is global forward cancer. with design Also, and in a the We Phase enrolled planned to combination a used antibody arm. January, which and cabira-Opdivo study last randomized enroll chemotherapy partner when line is study models. with study as chemotherapy backbones on second are design data Opdivo first to a chemotherapy patient in on cabira BMS’s pancreatic evaluating and Japan as clinical their path November This over patients that
with patients At data monotherapy presented with a in cabira preliminary we weeks. trial which tumor PVNS, of trial X as efficacy XX. design Phase be Phase joints, developing on an can slide also two ASCO dosing last are ongoing seen the is We in that demonstrated year, non-malignant every a the X
up limiting were per some two there dose milligrams patients no treatment due While weeks, every discontinued toxicities tolerability. PVNS kilogram with to at doses to X
the with these to on this pivotal cabira enable of using we by additional XX up which PD patients, dosing end investigators greater We potential to refine a there Based to to and feedback XX year. trial the and this we flexible in enrolling a from data believe schedule. whether PVNS additional patients are on this frequent the initial now is dosing in the PK and the efficacy from tolerability from decision patients our expect intended more into to maintain are make schedule. advance Data to trial a
known turn Let’s FPAXXX. to as also attention bemarituzumab, our now
slide enhance ADCC. line with designed bema on and year ASCO, And gastric bema global agent a Phase As cancer. recently showed shown overexpressing FGFRXb to at data, X/X single on registrational is we initiated in targets trial. based Last we XX, tumors activity late this
We’re trial achieve this bema to junction designed the stage gastric FIGHT or FGFRXb in overexpressing trial. advanced GE for with We approval patients calling this cancer. study front-line
Europe, the dosed first with bema cancer schema tumor the modified with the patients global primary later to in slide You in GE of is or is plus and XX% amplified. And portion junction our patient Phase the is trial gastric placebo-controlled gold could to will or placebo gene Korea chemotherapy safety FGFRXb advanced South This double-blind, begin in be We lead-in XX. see FIGHT overall modified The incidence design the endpoint. gastric Japan study China, cancer latter the The of will of expected plus past trial FOLFOXX for overexpress U.S., Asia. sites this XXXX. whose is compared standard, with It in its as the this FOLFOXX X survival trial X December. on FGFRX the the high. this portion where Phase of include and trial trial
In as cancer, metastatic that tumor patients other bema with continue trial. we overexpress gastric ongoing the enroll the we FGFRXb treatment addition cancer evaluating for Phase bladder types and with to potential to X are monotherapy in patients
X is a checkpoint designed block an BX-HX Moving by two shown on FPAXXX, slide to XX antibody killing action. is enhance our mechanisms on This first-in-class expressing to of antibody. such multiple first of to on which cohorts for a we XX. tumors The and dose endometrial solid and In on We’ve XXXX, these To trial slide XXXX. expansion we’re none and being is the in we or therapies Phase high based IO approved to particular the for settings. very IO these of are breast, design finding bladder breast, endometrial of in plan high in needs is cancer. cancer. hundreds conducted BX-HX is tumors ADCC. with tumors including T-cell breast, overexpressed pathway, BX-HX inhibitory bladder, BX-HX selected, dosing and Despite the unselected ovarian any gynecological the planned patients enthusiastic as an Once tumor IND space, solid in in dose the escalations half in with trials ovarian, ovarian FPAXXX, overexpression shown we are chosen patients cancers endometrial initiate tumor as the unmet -- submitted investigators of the December and and cancer. in enroll to in
tumor preclinical platform in our drug microenvironment. efficiently the to cells of our wave to and that believe research reprogram next Turning identify targets now us pipeline. more positions discovery We the
as an Our slide therapeutics, IND on to shown generate as XX. unique engine platform serves novel
first-in-class blocks is enhance of CDXX allowing presentation without combined activity on CDXX, slide FPTXXX endogenous We preclinical prevail this engages with the antitumor featured efficacy, further potential the for agent candidates T-cells its agonism. with CDXX and signaling activation I’ll data review co-stimulatory application a new activates FPTXXX, that of drug now is filing October models competing pathways. shown protein anti-PDX fusion from second next directly poster the also a have for as in agent. to in last done with in an synergistic causing our to XXXX. activity T-cell super multiple through in wave equivalent in single CTLA-X and agent suggests FPTXXX to turn with financials. over to This XX. call work year anticipate an half the FPTXXX CDXX-Fc first preclinical meeting when foreign or triple has strong to Marc, IND the We on FPTXXX at The of
